Preclinical evaluation of bozepinib in bladder cancer cell lines : modulation of the NPP1 enzyme
© 2023. The Author(s), under exclusive licence to Springer Nature B.V..
Bladder cancer (BC) is the most common cancer of the urinary tract. Bozepinib (BZP), a purine-derived molecule, is a potential compound for the treatment of cancer. Purinergic signaling consists of the activity of nucleosides and nucleotides present in the extracellular environment, modulating a variety of biological actions. In cancer, this signaling is mainly controlled by the enzymatic cascade involving the NTPDase/E-NPP family and ecto-5'-nucleotidase/CD73, which hydrolyze extracellular adenosine triphosphate (ATP) to adenosine (ADO). The aim of this work is to evaluate the activity of BZP in the purinergic system in BC cell lines and to compare its in vitro antitumor activity with cisplatin, a chemotherapeutic drug widely used in the treatment of BC. In this study, two different BC cell lines, grade 1 RT4 and the more aggressive grade 3 T24, were used along with a human fibroblast cell line MRC-5, a cell used to predict the selectivity index (SI). BZP shows strong antitumor activity, with notable IC50 values (8.7 ± 0.9 µM for RT4; 6.7 ± 0.7 µM for T24), far from the SI for cisplatin (SI for BZP: 19.7 and 25.7 for RT4 and T24, respectively; SI for cisplatin: 1.7 for T24). BZP arrests T24 cells in the G2/M phase of the cell cycle, inducing early apoptosis. Moreover, BZP increases ATP and ADP hydrolysis and gene/protein expression of the NPP1 enzyme in the T24 cell line. In conclusion, BZP shows superior activity compared to cisplatin against BC cell lines in vitro.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Purinergic signalling - (2023) vom: 31. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
da Silva, Álisson Coldebella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bladder cancer |
|---|
| Anmerkungen: |
Date Revised 31.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s11302-023-09975-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363983821 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363983821 | ||
| 003 | DE-627 | ||
| 005 | 20231226094511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11302-023-09975-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1213.xml |
| 035 | |a (DE-627)NLM363983821 | ||
| 035 | |a (NLM)37906424 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a da Silva, Álisson Coldebella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preclinical evaluation of bozepinib in bladder cancer cell lines |b modulation of the NPP1 enzyme |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature B.V. | ||
| 520 | |a Bladder cancer (BC) is the most common cancer of the urinary tract. Bozepinib (BZP), a purine-derived molecule, is a potential compound for the treatment of cancer. Purinergic signaling consists of the activity of nucleosides and nucleotides present in the extracellular environment, modulating a variety of biological actions. In cancer, this signaling is mainly controlled by the enzymatic cascade involving the NTPDase/E-NPP family and ecto-5'-nucleotidase/CD73, which hydrolyze extracellular adenosine triphosphate (ATP) to adenosine (ADO). The aim of this work is to evaluate the activity of BZP in the purinergic system in BC cell lines and to compare its in vitro antitumor activity with cisplatin, a chemotherapeutic drug widely used in the treatment of BC. In this study, two different BC cell lines, grade 1 RT4 and the more aggressive grade 3 T24, were used along with a human fibroblast cell line MRC-5, a cell used to predict the selectivity index (SI). BZP shows strong antitumor activity, with notable IC50 values (8.7 ± 0.9 µM for RT4; 6.7 ± 0.7 µM for T24), far from the SI for cisplatin (SI for BZP: 19.7 and 25.7 for RT4 and T24, respectively; SI for cisplatin: 1.7 for T24). BZP arrests T24 cells in the G2/M phase of the cell cycle, inducing early apoptosis. Moreover, BZP increases ATP and ADP hydrolysis and gene/protein expression of the NPP1 enzyme in the T24 cell line. In conclusion, BZP shows superior activity compared to cisplatin against BC cell lines in vitro | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bladder cancer | |
| 650 | 4 | |a Bozepinib | |
| 650 | 4 | |a NPP1 enzyme | |
| 650 | 4 | |a Purinergic system | |
| 700 | 1 | |a Scholl, Juliete Nathali |e verfasserin |4 aut | |
| 700 | 1 | |a de Fraga Dias, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Augusto Ferreira |e verfasserin |4 aut | |
| 700 | 1 | |a Morrone, Fernanda Bueno |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz-López, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Conejo-García, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Joaquín María |e verfasserin |4 aut | |
| 700 | 1 | |a Sévigny, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Figueiró, Fabrício |e verfasserin |4 aut | |
| 700 | 1 | |a Battastini, Ana Maria Oliveira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Purinergic signalling |d 2004 |g (2023) vom: 31. Okt. |w (DE-627)NLM160620074 |x 1573-9546 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:31 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11302-023-09975-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 31 |c 10 | ||